Loading filters...
50 results(scroll for more)
SCLCAdvanced/Metastatic (IV)2026
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer.
Akagi K et al. Lung Cancer. 2026
SCLCAdvanced/Metastatic (IV)2026
Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer.
Cooper AJ et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.
Yiu CH et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
Lopez JS et al. Br J Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.
Kinehara Y et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.
Zhong H et al. Lancet Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Hayashi H et al. Lung Cancer. 2026
ImmunotherapyAll Stages2026
Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
Senan S et al. J Thorac Oncol. 2026
SCLCAdvanced/Metastatic (IV)2026
FDA Approval Summary: Tarlatamab for the Treatment of Extensive-Stage Small Cell Lung Cancer.
Liu Y et al. Clin Cancer Res. 2026
RET fusionAdvanced/Metastatic (IV)2026
RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.
Sun Z et al. Lung Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.
Reck M et al. Lung Cancer. 2026
SCLCAll Stages2026
Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database.
Wang J et al. Lung Cancer. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).
Stensland EM et al. Lung Cancer. 2026
SCLCAdvanced/Metastatic (IV)2026
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer.
Aiba T et al. Lung Cancer. 2026
RET fusionAdvanced/Metastatic (IV)2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Besse B et al. J Clin Oncol. 2026
SCLCAll Stages2026
Brief Report: Low Delta-like Ligand 3 expression and T Cell Exhaustion Drive Resistance to Tarlatamab combined with anti-PD-1 in Small-Cell Lung Cancer.
Fukuda A et al. J Thorac Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer.
Zheng J et al. Cancer Discov. 2026
SCLCAdvanced/Metastatic (IV)2026
Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice.
Blocker S et al. Eur J Cancer. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial.
Levy B et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.
Scherpereel A et al. J Clin Oncol. 2026
SCLCAll Stages2026
Tumor Inflammation-Associated Neurotoxicity Masquerading as Severe Immune Effector Cell-Associated Neurotoxicity Syndrome in a Patient With SCLC Treated With Tarlatamab: A Case Report.
Torasawa M et al. J Thorac Oncol. 2026
SCLCAdvanced/Metastatic (IV)2026
Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences.
Lamberti G et al. Lung Cancer. 2026
RET fusionAll Stages2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al. Clin Cancer Res. 2026
ImmunotherapyAll Stages2026
Improving anti-CTLA-4 therapies through peptide masking and fragment crystallizable non‑fucosylation: preclinical characterization of three novel antibodies.
Jhatakia A et al. Clin Cancer Res. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
Aldea M et al. Ann Oncol. 2026
SCLCAdvanced/Metastatic (IV)2026
Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1.
Lv D et al. Lung Cancer. 2026
GeneralEarly (I-III)2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
Higgins KA et al. J Clin Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Gray JE et al. Clin Cancer Res. 2026
KRAS G12CAll Stages2026
Emerging landscape of KRAS inhibitors in cancer treatment.
Riedl JM et al. Cancer Cell. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib.
Piotrowska Z et al. Cancer Discov. 2026
SCLCAdvanced/Metastatic (IV)2026
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and PD-L1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.
Fan Y et al. J Thorac Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
Yu HA et al. Clin Cancer Res. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer.
Wu X et al. Clin Cancer Res. 2026
SCLCAll Stages2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients.
Ponce S et al. J Thorac Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD.
Riess JW et al. Ann Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.
Prabhakaran S et al. Cancer Res. 2026
EGFR mutantAll Stages2026
Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer.
Liu T et al. Cancer Res. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.
Zhou C et al. Lung Cancer. 2026
EGFR mutantAll Stages2026
Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases.
Hashimoto K et al. Lung Cancer. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
Paz-Ares L et al. Lung Cancer. 2026
KRAS G12CAll Stages2026
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC.
Cavazzoni A et al. Lung Cancer. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
Barsouk A et al. Lung Cancer. 2026
ALK fusionAll Stages2026
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Schneider JL et al. Lung Cancer. 2026
EGFR mutantAll Stages2026
Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm.
Vasiliki N et al. Lung Cancer. 2026
ImmunotherapyEarly (I-III)2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
Goss GD et al. J Clin Oncol. 2026
EGFR mutantAdvanced/Metastatic (IV)2026
Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.
Ross JS et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.
Kim DH et al. Lung Cancer. 2026
EGFR mutantAll Stages2026
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
Chen MF et al. J Thorac Oncol. 2026
EGFR mutantAll Stages2026
GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.
Zhang X et al. J Thorac Oncol. 2026
ImmunotherapyAdvanced/Metastatic (IV)2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
Reck M et al. J Thorac Oncol. 2026